Frontier Health

frontierhealth.org

Frontier Health's vision is to establish and provide accessible, high quality care. Frontier Health, a 501(c) 3, is the area’s leading provider of mental health, substance abuse, co-occurring, developmental and intellectual disabilities, recovery and vocational rehabilitation services for adults, children and youth at 64 sites in Northeast Tennessee and Southwest Virginia. Frontier Health's mission is to provide quality services that encourage people to achieve their full potential. To provide those services, Frontier’s 1,005 employees traveled 1.74 million miles during FY 2014-15 in a 12,000-square-mile coverage area for 48,862 individuals. Frontier Health also provides an adult residential treatment for addiction and/or co-occurring disorders, services for individuals who are deaf or hard of hearing, domestic violence victims, youth in crisis, runaways, foster care and adoption services.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

CAJAL NEUROSCIENCE LAUNCHES WITH $96 MILLION TO TRANSFORM TARGET AND DRUG DISCOVERY IN NEURODEGENERATION

Cajal Neuroscience | November 30, 2022

news image

Cajal Neuroscience, a biotechnology company integrating human genetics, functional genomics and advanced microscopy to discover novel targets and therapeutics for neurodegeneration, launched today with the completion of a $96 million Series A financing. Cajal is uniquely focused on the mechanistic, spatial and temporal complexity of neurodegeneration, integrating deep expertise in neuroscience, neuroanatomy and computational biology with state-of-the-art technologies for high-throughput function...

Read More

Industrial Impact

IMAGINAB EXECUTES NEW LICENSE AND SUPPLY AGREEMENT FOR CD8 IMMUNOPET TECHNOLOGY WITH TRISALUS LIFE SCIENCES

ImaginAb | November 23, 2022

news image

ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam imaging agent and radiopharmaceutical therapy products, is pleased to announce the signing of a new non-exclusive License and Supply Agreement with TriSalus Life Sciences, Inc. an oncology therapeutics company integrating immunotherapy with disruptive delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors. Under the terms of the agreement, ImaginAb wil...

Read More

GENSCRIPT FILES FOR EMERGENCY USE AUTHORIZATION OF RAPID SARS-COV-2 NEUTRALIZATION ANTIBODY DETECTION KIT

GenScript | June 03, 2020

news image

GenScript Biotech Corp., the world's leading research reagent provider, announced today that the company has filed for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) to market its cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit. This is the first test submitted for regulatory approval that specifically detects neutralizing antibodies to SARS-CoV-2, the virus that causes COV-19, without the use of live virus. Current serological antibody tests...

Read More

Industry Outlook

CABALETTA BIO AND WUXI ADVANCED THERAPIES ANNOUNCE EXPANSION OF GMP MANUFACTURING AGREEMENT TO INCLUDE CABA-201

Globenewswire | August 23, 2023

news image

Cabaletta Bio, Inc. a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that it has entered into certain work orders relating to Good Manufacturing Practice (GMP) manufacturing under its existing master services agreement with WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO). As part of the agreement, WuXi ...

Read More
news image

Medical

CAJAL NEUROSCIENCE LAUNCHES WITH $96 MILLION TO TRANSFORM TARGET AND DRUG DISCOVERY IN NEURODEGENERATION

Cajal Neuroscience | November 30, 2022

Cajal Neuroscience, a biotechnology company integrating human genetics, functional genomics and advanced microscopy to discover novel targets and therapeutics for neurodegeneration, launched today with the completion of a $96 million Series A financing. Cajal is uniquely focused on the mechanistic, spatial and temporal complexity of neurodegeneration, integrating deep expertise in neuroscience, neuroanatomy and computational biology with state-of-the-art technologies for high-throughput function...

Read More
news image

Industrial Impact

IMAGINAB EXECUTES NEW LICENSE AND SUPPLY AGREEMENT FOR CD8 IMMUNOPET TECHNOLOGY WITH TRISALUS LIFE SCIENCES

ImaginAb | November 23, 2022

ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam imaging agent and radiopharmaceutical therapy products, is pleased to announce the signing of a new non-exclusive License and Supply Agreement with TriSalus Life Sciences, Inc. an oncology therapeutics company integrating immunotherapy with disruptive delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors. Under the terms of the agreement, ImaginAb wil...

Read More
news image

GENSCRIPT FILES FOR EMERGENCY USE AUTHORIZATION OF RAPID SARS-COV-2 NEUTRALIZATION ANTIBODY DETECTION KIT

GenScript | June 03, 2020

GenScript Biotech Corp., the world's leading research reagent provider, announced today that the company has filed for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) to market its cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit. This is the first test submitted for regulatory approval that specifically detects neutralizing antibodies to SARS-CoV-2, the virus that causes COV-19, without the use of live virus. Current serological antibody tests...

Read More
news image

Industry Outlook

CABALETTA BIO AND WUXI ADVANCED THERAPIES ANNOUNCE EXPANSION OF GMP MANUFACTURING AGREEMENT TO INCLUDE CABA-201

Globenewswire | August 23, 2023

Cabaletta Bio, Inc. a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that it has entered into certain work orders relating to Good Manufacturing Practice (GMP) manufacturing under its existing master services agreement with WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO). As part of the agreement, WuXi ...

Read More